Page 291 - Drug Class Review

Drug Effectiveness Review Project

Alzheimer Drugs Authors: Wong et al. 67 Year: 1999 Country: Taiwan Parke-Davis Pharmaceutical Division of Warner-Lambert Company To evaluate the efficacy and safety of TAC in Chinese patients with probable AD Study design: RCT Setting: NR Sample size: 100 placebo tacrine N/A 120 mg/d titrated at 30 mg/d 30 weeks 30 weeks 25 75 > 50 yrs old; met NINCDS criteria for probable AD with the presence of symptoms for at least 1 year; dementia was mild to moderate as determined by CDR; baseline MMSE score of 10 - 26 Cardiac disease; stroke; diabetes; hepat

Final Report Update 1 Adverse Events STUDY: FUNDING: RESEARCH OBJECTIVE: DESIGN: INTERVENTION: Dose: Duration: Sample size: INCLUSION: EXCLUSION: OTHER MEDICATIONS/ INTERVENTIONS ALLOWED: Alzheimer's Drugs